New drug with chemo for newly diagnosed osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding trilaciclib to standard chemotherapy before surgery for patients with newly diagnosed, high-grade osteosarcoma. Trilaciclib may help protect healthy cells during chemo treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classic, high-grade osteosarcoma that has not spread widely (stage II or III).
- You have not received any prior chemotherapy or other systemic cancer treatment.
- You are able to perform daily activities with little to no help (ECOG 0 or 1).
- You have at least one tumor that can be measured on a CT scan.
- You agree to use effective birth control during treatment and for 6 months after the last dose.
- Your vital organs (like heart, liver, kidneys) are working well enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial tests whether the drug trilaciclib can reduce low blood cell counts caused by chemotherapy in people with Ewing's sarcoma. If you qualify, you may receive a medication that could help protect your bone marrow during treatment.
This study tests a new drug called trilaciclib, which is added to standard chemotherapy given before breast cancer surgery. The goal is to see if it helps shrink the tumor and possibly reduces side effects like low blood cell counts, making the treatment easier to tolerate.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.